The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
Cholinergic deficiency associated mainly with the degeneration of neurons in the nucleus basalis of Meynert is one of the key factors of the development of cognitive impairments in Alzheimer’s disease (AD). Cholinesterase inhibitors are used to treat mild and moderate dementia in AD. However, the wi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-09-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/153 |
| _version_ | 1827062901760851968 |
|---|---|
| author | Elena Evgenyevna Vasenina O S Levin |
| author_facet | Elena Evgenyevna Vasenina O S Levin |
| author_sort | Elena Evgenyevna Vasenina |
| collection | DOAJ |
| description | Cholinergic deficiency associated mainly with the degeneration of neurons in the nucleus basalis of Meynert is one of the key factors of the development of cognitive impairments in Alzheimer’s disease (AD). Cholinesterase inhibitors are used to treat mild and moderate dementia in AD. However, the wide use of this group of agents is limited by the high incidence of some side effects. The application of a novel rivastigmine transdermal (patch) formulation substantially reduces the risk of adverse reactions chiefly associated with a negative effect on the gastrointestinal tract and increases treatment adherence. Thus, there is a rise in the number of patients who may be given the drug in the optimal therapeutic dose for a long time. |
| first_indexed | 2024-04-10T02:04:05Z |
| format | Article |
| id | doaj.art-67a9345af8184c2ebf6847195a443438 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2025-02-18T20:04:15Z |
| publishDate | 2012-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-67a9345af8184c2ebf6847195a4434382024-10-17T16:15:20ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422012-09-0143969910.14412/2074-2711-2012-413153The specific features of using a rivastigmine transdermal formulation in Alzheimer’s diseaseElena Evgenyevna VaseninaO S LevinCholinergic deficiency associated mainly with the degeneration of neurons in the nucleus basalis of Meynert is one of the key factors of the development of cognitive impairments in Alzheimer’s disease (AD). Cholinesterase inhibitors are used to treat mild and moderate dementia in AD. However, the wide use of this group of agents is limited by the high incidence of some side effects. The application of a novel rivastigmine transdermal (patch) formulation substantially reduces the risk of adverse reactions chiefly associated with a negative effect on the gastrointestinal tract and increases treatment adherence. Thus, there is a rise in the number of patients who may be given the drug in the optimal therapeutic dose for a long time.https://nnp.ima-press.net/nnp/article/view/153alzheimer’s diseasecholinesterase inhibitorsrivastigminetransdermal administration |
| spellingShingle | Elena Evgenyevna Vasenina O S Levin The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease Неврология, нейропсихиатрия, психосоматика alzheimer’s disease cholinesterase inhibitors rivastigmine transdermal administration |
| title | The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease |
| title_full | The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease |
| title_fullStr | The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease |
| title_full_unstemmed | The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease |
| title_short | The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease |
| title_sort | specific features of using a rivastigmine transdermal formulation in alzheimer s disease |
| topic | alzheimer’s disease cholinesterase inhibitors rivastigmine transdermal administration |
| url | https://nnp.ima-press.net/nnp/article/view/153 |
| work_keys_str_mv | AT elenaevgenyevnavasenina thespecificfeaturesofusingarivastigminetransdermalformulationinalzheimersdisease AT oslevin thespecificfeaturesofusingarivastigminetransdermalformulationinalzheimersdisease AT elenaevgenyevnavasenina specificfeaturesofusingarivastigminetransdermalformulationinalzheimersdisease AT oslevin specificfeaturesofusingarivastigminetransdermalformulationinalzheimersdisease |